We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00691522
Recruitment Status : Terminated
First Posted : June 5, 2008
Last Update Posted : January 9, 2009
Celtic Pharma Development Services
Information provided by:

June 2, 2008
June 5, 2008
January 9, 2009
November 2008
August 2009   (Final data collection date for primary outcome measure)
Not Provided
To investigate the effect of 3 different regimens SC of hCRF on the reduction of PBE in patients with primary malignant or metastatic brain tumors as defined by MRI indexes. [ Time Frame: MRI-derived measurements of the differences in mean diffusivity ]
Complete list of historical versions of study NCT00691522 on ClinicalTrials.gov Archive Site
Not Provided
To evaluate the safety of hCRF in the treatment of PBE patients with primary malignant or metastatic brain tumors To establish the percentage of responders as measured by clinical and radiographic means To identify tumor and PBE changes [ Time Frame: General laboratory, physical and neurological examinations, AEs/SAEs ]
Not Provided
Not Provided
Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)
Open-Label, Imaging Study of Human Corticotropin-Releasing Factor (hCRF) for The Reduction of Peritumoral Brain Edema (PBE) in Patients With Primary Malignant or Metastatic Brain Tumors
This is a phase II, multicenter, open-label, imaging study of hCRF in the reduction of PBE in patients with primary malignant or metastatic brain tumors. Approximately 30 to 60 patients will be assigned to 1 of 3 treatment groups and receive study drug for up to 28 days
The purpose of this study is to investigate the effect of 3 different regimens of subcutaneous (SC) administered hCRF (1.0 mg every [Q] 8 hours [h], 1.5 mg Q12h, and 1.0 mg Q12h) on the reduction of PBE in patients with primary malignant or metastatic brain tumors as defined by MRI indexes.
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Peritumoral Brain Edema
Drug: Xerecept
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age or older.
  • Written informed consent has been provided and documented.
  • Primary malignant or metastatic brain tumor that is either asymptomatic or symptomatic patients with the life expectancy estimation of 3 months or more
  • A pretreatment MRI brain scan must identify at least 1 dominant tumor lesion and related PBE that is radiologically (or visibly) distinct from the main tumor mass; the combined tumor-edema lesion must be > 2 cm in longest diameter (for at least 1 slice) and visible in 3 consecutive, 4 mm sections on MRI.
  • No dexamethasone or anti-angiogenic treatment for at least 14 days prior to the Baseline and throughout the study.
  • A Karnofsky Performance Score > 60 at Screening (Visit 1) and at Baseline
  • A negative serum pregnancy test at the Screening (Visit 1) is required for women of childbearing potential.

Exclusion Criteria:

  • • Low-grade gliomas, recurrent gliomas, suspected lymphoma, or known human immunosuppressive virus (HIV) infection.

    • Patients requiring surgery, radiosurgery or radiation surgery therapy
    • Patients experiencing severe symptoms related to PBE
    • Patients where MRI is contraindicated for any reason.
    • Signs and/or symptoms of relatively severe cerebral herniation.
    • Concurrent enrollment in any other investigational drug or device study, or plan to enroll in such a study during the 3 to 4 weeks of study treatment.
    • Systemic corticosteroid use (with the exception of inhalers for asthma).
    • Use of dexamethasone (eg, as an anti-emetic) during screening or during the study
    • Use of anti-angiogenic/anti-vascular endothelial growth factor (VEGF) therapy or anticonvulsant therapy (if patient's liver function tests (LFTs) are > 3 times upper limit of normal) 14 days prior to randomization
    • Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal, or endocrine metabolic disease, which in the opinion of the Investigator or the Medical Monitor, would put the patient as unusual risk during study participation.
    • Known renal insufficiency or screening glomerular filtration rate (GFR) < 60 mL/min/1.73 m2.
    • Central nervous system infection, human immunosuppressive virus (HIV) positive or ongoing infectious process.
    • For female patients: pregnancy, breastfeeding or refusal to practice birth control if of childbearing potential during the study.
    • Inability of the patient to follow the treatment regimen.
    • Known history of methionine allergy.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
CPDS 0701
Not Provided
Not Provided
Celtic Pharma Development Services
Not Provided
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP